





Risk assessment and mitigation strategies
Appropriate Single-use System Applications
Routes of contamination in the process
Filter categorization
Moderately critical filters and risk approach
Critical filters and risk approach
Filter qualification





















#### Map Out the Process Flow of Raw Materials Each step may introduce microbes into the process

Handling	Water transfer (cleaning, compounding)
Transport of materials in the facility	Compounding
Testing	Mixing
Sampling	Hold times
Transfer into different packaging	Dispensing
Storage conditions	Sampling
Weighing	Room Cleaning
Sieving	Equipment Cleaning
Crushing	Personnel Hygiene
Sifting	
How do I assess the risk of these parameters?	
11	Merck







#### Prevent Raw Material Contamination Raw Material Selection

#### Prevent

- Remove animal derived components
  - Caution! Serum-free does not mean mycoplasma free
  - Consider chemical free
- Select raw material quality grade
- Pharmaceutical grade versus analytical grade
- Audit vendor

#### Mitigate


- Pre-treat components
  - Choose treatments effective for viral and bacterial reduct

#### Detect

- Screen raw material with rapid tests
  - Caution! Sample sizes versus kG to tons of material




Merck









# "Contaminant-free" is only as good as the detection method used ${\ensuremath{\textit{Microbiological Detection}}}$

#### Classical Methods

Most developed in the 19th century

- Microscopy
- Growth-based methods

#### Benefits

- Easy to implement
- · Easy to qualify
- Larger sample volumes possible

#### Limitations

- No universal medium or growth conditions
- Only detect those microbes capable of replicating in the chosen test medium under the specified conditions
- · Can take days to weeks for a result

#### **Rapid Methods**

Developed over the past 30 years but slow adoption rate

- qPCR
- TMA
- Microcolony growth detection

#### Benefits

- · Rapid results
- Higher sensitivity for equal volume compared to classical methods

#### Limitations

- More extensive validation
- Higher expertise required
- False positives doesn't distinguish viable cells
- Small sample size
- Often destructive
  - Split samples needed for identification Merck



# Limits of Detection Sampling Volumes

#### Sampling

- Vessel Liters to 10,000+ Liters
- Sample Volume
   Less than 1 Liter

#### Assay

- Removed from sample volume
- Milliliter to microliter



#### **Limits of Detection**

#### Sampling

Assume a 1 L sample from a 10,000 L Bioreactor Assay requires a 1 mL sample for testing


CFU per Liter	10	1,000	10,000
CFU per mL	0.01	1	100
Probability an organism will <b>NOT</b> be detected in the sample	0.99	0.9	0.37

#### Assay Sensitivity

LOD PCR for Leptospira:	100 CFU (equivalent)
LOD PCR for Mycoplasma:	1-10 CFU (equivalent)
LOD by light microscopy @ 400 x:	10 <sup>5</sup> to 10 <sup>6</sup> cells

Merck





#### **Some Risk Assessment Considerations for Filters**

Fluid classification Fluids labeled "sterile" have the highest risk

**Dosage form** Injectables without preservative have highest risk

Room classification Lower grade brings greater risk if there is a breech

**Location of filter in the process** The closer to the final product the greater risk

Detectability of poor filtration performance No in-line testing has the highest risk **Contact time** The longer the contact time the greater the risk

**Process conditions** The more aggressive the conditions, the greater the risk

Fluid pretreatment Less pretreatment has greater risk


Fluid posttreatment No downstream removal of low MW material has greater risk

**Filter pretreatment** The more aggressive the pretreatment (e.g. SIP), the greater the risk


Prior history If there have been previous filter related issues, the risk is greater
























































#### Challenge: Joining Two Sterile Lines - Tube Welder


A device where two sterile tubing lines are together heat welded Tubing lines are inserted into holders. Then a heated blade cut the tubes allowing the lines to fuse together leaving a sterile fluid pathway.
















































#### Filters Can Be Divided into 3 Groups - Definitions

#### Service

#### The filter does not affect product quality

- Where process fluids come from facility-wide systems, are not tailored to a specific process and do not have contact with the drug substance or potential drug substance.
- Part of a No-Impact System Where the equipment of system has no impact, direct or indirect, on product quality (ISPE Commissioning & Qualification Baseline Guide (2001))
- Examples: distribution gas filter, water prefilter

#### Moderately critical

#### The filter indirectly affects product quality

- Where process fluids "will not be in direct contact with exposed sterile product or surfaces." (PDA TR40)
- Part of an Indirect Impact System equipment or system expected to have incidental or secondary impact on product quality (ISPE Commissioning & Qualification Baseline Guide (2001))

#### - Examples: vent filter in a grade D/C area, bioburden reduction filter


#### **Critical Applications**


#### The filter directly affects product quality

- Where process fluids "are in direct contact with sterile final product or critical surfaces of the associated equipment." (PDA TR40)
- Part of Direct Impact System equipment or system that will have focused and immediate impact on product quality (ISPE Commissioning & Qualification Baseline Guide (2001))
   Examples: vent filter on a sterile hold vessel, sterile liquid filter

Merck











#### **Purpose of Moderately Critical Filtration**

Removal of undesirable microorganisms from process fluids


- -Prevent contamination of the fermentation
- -Cell culture media and air
- -Formulation and process tanks
- Chromatography systems
- -Buffers, washing fluids
- Process intermediates


Reduction of bioburden in purification process steps

- -Low bioburden means low endotoxin
- -Low / controlled / specified bioburden may be a compliance requirement


Merck
































# Annex 2 Manufacture of Biological active substances and Medicinal Products for Human Use

For biological materials that cannot be sterilized (e.g. by filtration), processing must be conducted aseptically to minimise the introduction of contaminants.

5. As part of the control strategy, the degree of environmental control of particulate and microbial contamination of the production premises should be adapted to the active substance, intermediate or finished product and the production step, bearing in mind the potential level of contamination of the starting materials and the risks to the product.

6. Manufacturing and storage facilities, processes and environmental classifications should be designed to prevent the extraneous contamination of products. Prevention of contamination is more appropriate than detection and removal

8 c) Live organisms and spores are prevented from entering non-related areas or equipment by addressing all potential routes of cross-contamination and utilizing single use components and engineering measures such as closed systems.

8 e) Environmental monitoring specific for the micro-organism being manufactured, where the microorganisms are capable of persistence in the manufacturing environment and where methods are available, is conducted in adjacent areas during manufacture and after completion of cleaning and decontamination.

8 f) Products, equipment, ancillary equipment (e.g. for calibration and validation) and disposable items are only moved within and removed from such areas in a manner that prevents contamination of other areas, other products and different product

Merck



62

# Annex 2 Manufacture of Biological active substances and Medicinal Products for Human Use

13. Equipment used during handling of live organisms and cells, including those for sampling, should be designed to prevent any contamination during processing.

16. Air vent filters should be hydrophobic and validated for their scheduled life span with integrity testing at appropriate intervals based on appropriate QRM principles.

33. Given that the risks from the introduction of contamination and the consequences to the finished product is the same irrespective of the stage of manufacture, establishment of a control strategy to protect the product and the preparation of solutions, buffers and other additions should be based on the principles and guidance contained in the appropriate sections of Annex 1.

34. Where sterilization of starting and raw materials is required, it should be carried out where possible by heat. Where necessary, other appropriate methods may also be used for inactivation of biological materials (e.g. irradiation and filtration).

51. The growth promoting properties of culture media should be demonstrated to be suitable for its intended use. If possible, media should be sterilized in situ. In-line sterilizing filters for routine addition of gases, media, acids or alkalis, anti-foaming agents etc. to fermenters should be used where possible.

52. Addition of materials or cultures to fermenters and other vessels and sampling should be carried out under carefully controlled conditions to prevent contamination. Care should be taken to ensure that vessels are correctly connected when addition or sampling takes place.

Merck

